Université Catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue Mounier 73, B1.73.12, 1200 Brussels, Belgium.
Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France; LabEx DEVweCAN, Université de Lyon, Lyon, France.
Int J Pharm. 2019 Oct 5;569:118588. doi: 10.1016/j.ijpharm.2019.118588. Epub 2019 Aug 1.
The purpose of this study was to investigate the feasibility of an intravenously administered combinational therapy using lipid nanocapsules (LNCs) as a drug delivery carrier for the treatment of different cancers. Therefore, we encapsulated 6 anticancer drugs within LNCs. Their size was approximately 50 nm. Except for oxaliplatin, their encapsulation efficiency, which was measured by different analytical methods, varied between 75% for SN38 to 100% for regorafenib. The in vitro studies showed a nonsignificant difference between the cytotoxicity of free and encapsulated drugs and a significant decrease in haemolysis by encapsulation in LNCs. Finally, the in vivo experiment showed that a combinational regimen of SN38-LNCs and regorafenib-LNCs abates CT26 murine colorectal cancer growth and increases median survival time.
本研究旨在探讨静脉内给予脂质纳米胶囊（LNC）作为药物递送载体治疗不同癌症的联合治疗的可行性。因此，我们将 6 种抗癌药物包封在 LNC 中。其粒径约为 50nm。除奥沙利铂外，通过不同的分析方法测量的包封效率在 SN38 的 75%到regorafenib 的 100%之间变化。体外研究表明，游离药物和包封药物的细胞毒性无显著差异，而 LNC 包封可显著降低溶血。最后，体内实验表明，SN38-LNC 和 regorafenib-LNC 的联合方案可抑制 CT26 结直肠癌细胞生长并延长中位生存时间。
